Victory Pharma, Inc. has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc.

Through the acquisition, Victory Pharma has expanded its product portfolio with the addition of anti-infective products MOXATAG and KEFLEX as well as the PULSYS drug delivery technology platform. The product additions complement Victory’s current products, such as NAPRELAN, which the company markets to primary care and specialist physicians.

“This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products,” said Matt Heck, president and chief executive officer of Victory Pharma. “The addition of these products balances our portfolio nicely, as NAPRELAN’s highest period of utilization is in the spring and summer, while MOXATAG’s utilization peaks during the flu season. And we believe MOXATAG will substantially benefit from our management team’s prior, successful experience marketing anti-infective products.” MOXATAG is the only FDA-approved, once-daily formulation of amoxicillin, and is indicated for the treatment of tonsillitis and/or pharyngitis. MOXATAG utilizes PULSYS technology to deliver drug at set intervals over a 24 hour period, whereas other amoxicillin products require multiple times daily dosing. Reduced dosing frequency can improve therapy compliance, which is potentially important given patient non-compliance is widely-recognized as the primary reason for antibiotic therapy failure, and non-compliant patients have been shown to have a 175 percent greater chance of infection recurrence.